{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T02:35:31Z","timestamp":1792204531942,"version":"4.4.0"},"reference-count":125,"publisher":"American Academy of Pediatrics (AAP)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,5,1]]},"abstract":"<jats:p>Hidradenitis suppurativa is a chronic inflammatory skin disorder primarily affecting apocrine gland-bearing areas, including the axillae, groin, and buttocks. It is reported in up to 2% of Western populations and with increasing incidence in children and adults. Nearly one-third of hidradenitis suppurativa cases occur in pediatric patients and nearly half of patients endorse initial symptoms in childhood. To date, there are few clinical studies and guidelines for pediatric hidradenitis suppurativa. Here, we review the epidemiology, clinical presentation, comorbidities, and management of pediatric hidradenitis suppurativa. We discuss barriers contributing to delays in diagnosis and the significant physical and emotional impact of the disease on children and adolescents.<\/jats:p>","DOI":"10.1542\/peds.2022-061049","type":"journal-article","created":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T04:15:22Z","timestamp":1682568922000},"source":"Crossref","is-referenced-by-count":35,"title":["Hidradenitis Suppurativa in Pediatric Patients"],"prefix":"10.1542","volume":"151","author":[{"given":"Colleen H.","family":"Cotton","sequence":"first","affiliation":[{"name":"aDepartment of Dermatology, George Washington School of Medicine and Health Sciences, Washington, District of Columbia"},{"name":"bDivision of Dermatology, Children\u2019s National Hospital, Washington, District of Columbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stella X.","family":"Chen","sequence":"additional","affiliation":[{"name":"cBoston Children\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadaf H.","family":"Hussain","sequence":"additional","affiliation":[{"name":"cBoston Children\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Lara-Corrales","sequence":"additional","affiliation":[{"name":"dThe Hospital for Sick Children, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea L.","family":"Zaenglein","sequence":"additional","affiliation":[{"name":"ePenn State Hershey Medical Center, Penn State Children\u2019s Hospital, Hershey, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2023,4,27]]},"reference":[{"key":"2023111014150755300_B1","article-title":"Dictionnaire de medecine, un repertoire general des sciences medicales sous la rapport theorique et practique","volume-title":"Aisselle","author":"Velpeau","year":"1833","edition":"2nd ed."},{"issue":"4","key":"2023111014150755300_B2","first-page":"447","article-title":"Etudes sur les tumeurs de la peau; des quelques maladies des glandes sudoriparies","volume":"5","author":"Verneuil","year":"1854","journal-title":"Arch Gen Med"},{"key":"2023111014150755300_B3","first-page":"537","article-title":"De l\u2019hidrosadenite phlegmoneuse et des abces sudoripares","volume":"2","author":"Verneuil","year":"1864","journal-title":"Arch Gen Med"},{"key":"2023111014150755300_B4","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1001\/archderm.1939.01480190111010","article-title":"Hidradenitis suppurativa; abscess of the apocrine sweat glands","volume":"39","author":"Brunsting","year":"1939","journal-title":"Arch Derm Syphilol"},{"issue":"6","key":"2023111014150755300_B5","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1001\/archderm.1955.03730360068008","article-title":"The pathogenesis of hidradenitis suppurativa in man","volume":"72","author":"Shelley","year":"1955","journal-title":"Arch Dermatol"},{"issue":"5","key":"2023111014150755300_B6","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1046\/j.1365-2133.2000.03476.x","article-title":"The clinical genetics of hidradenitis suppurativa revisited","volume":"142","author":"Von Der Werth","year":"2000","journal-title":"Br J Dermatol"},{"issue":"1","key":"2023111014150755300_B7","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jaad.2019.02.067","article-title":"North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian Hidradenitis Suppurativa Foundations: part I: diagnosis, evaluation, and the use of complementary and procedural management","volume":"81","author":"Alikhan","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"2023111014150755300_B8","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1159\/000431175","article-title":"Hidradenitis suppurativa\/acne inversa: criteria for diagnosis, severity assessment, classification and disease evaluation","volume":"231","author":"Zouboulis","year":"2015","journal-title":"Dermatology"},{"issue":"12","key":"2023111014150755300_B9","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1001\/jamadermatol.2022.4564","article-title":"Evaluation of hidradenitis suppurativa diagnostic criteria in pediatric patients","volume":"158","author":"Kittler","year":"2022","journal-title":"JAMA Dermatol"},{"issue":"4","key":"2023111014150755300_B10","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1001\/jamadermatol.2020.5435","article-title":"Hidradenitis suppurativa in the pediatric population: an international, multicenter, retrospective, cross-sectional study of 481 pediatric patients","volume":"157","author":"Liy-Wong","year":"2021","journal-title":"JAMA Dermatol"},{"issue":"7","key":"2023111014150755300_B11","doi-asserted-by":"crossref","first-page":"e0200683","DOI":"10.1371\/journal.pone.0200683","article-title":"Hidradenitis suppurativa (HS) prevalence, demographics and management pathways in Australia: a population-based cross-sectional study","volume":"13","author":"Calao","year":"2018","journal-title":"PLoS One"},{"issue":"4","key":"2023111014150755300_B12","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1111\/bjd.16101","article-title":"Population-based clinical practice research datalink study using algorithm modelling to identify the true burden of hidradenitis suppurativa","volume":"178","author":"Ingram","year":"2018","journal-title":"Br J Dermatol"},{"issue":"8","key":"2023111014150755300_B13","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1001\/jamadermatol.2017.0201","article-title":"Sex- and age-adjusted population analysis of prevalence estimates for hidradenitis suppurativa in the United States","volume":"153","author":"Garg","year":"2017","journal-title":"JAMA Dermatol"},{"issue":"10","key":"2023111014150755300_B14","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1016\/j.jid.2018.04.001","article-title":"Prevalence estimates for hidradenitis suppurativa among children and adolescents in the United States: a gender- and age-adjusted population analysis","volume":"138","author":"Garg","year":"2018","journal-title":"J Invest Dermatol"},{"issue":"20","key":"2023111014150755300_B15","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1001\/jama.2017.16691","article-title":"Hidradenitis suppurativa: advances in diagnosis and treatment","volume":"318","author":"Saunte","year":"2017","journal-title":"JAMA"},{"issue":"9","key":"2023111014150755300_B16","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1001\/jamadermatol.2021.2865","article-title":"Differences between children and adults with hidradenitis suppurativa","volume":"157","author":"Hallock","year":"2021","journal-title":"JAMA Dermatol"},{"issue":"8","key":"2023111014150755300_B17","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1001\/jamadermatol.2019.0478","article-title":"Distribution of self-reported hidradenitis suppurativa age at onset","volume":"155","author":"Naik","year":"2019","journal-title":"JAMA Dermatol"},{"issue":"1","key":"2023111014150755300_B18","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1159\/000493465","article-title":"Adolescent-onset hidradenitis suppurativa: prevalence, risk factors and disease features","volume":"235","author":"Molina-Leyva","year":"2019","journal-title":"Dermatology"},{"issue":"3","key":"2023111014150755300_B19","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.clindermatol.2014.12.007","article-title":"Hidradenitis suppurativa in prepubescent and pubescent children","volume":"33","author":"Scheinfeld","year":"2015","journal-title":"Clin Dermatol"},{"issue":"3","key":"2023111014150755300_B20","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jaad.2014.11.017","article-title":"Correlation of early-onset hidradenitis suppurativa with stronger genetic susceptibility and more widespread involvement","volume":"72","author":"Deckers","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"2023111014150755300_B21","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/pde.13466","article-title":"Hidradenitis suppurativa in children: the Henry Ford experience","volume":"35","author":"Braunberger","year":"2018","journal-title":"Pediatr Dermatol"},{"issue":"4","key":"2023111014150755300_B22","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.jaad.2021.12.062","article-title":"Racial and ethnic health disparities in dermatology in the United States. Part 2: disease-specific epidemiology, characteristics, management, and outcomes","volume":"87","author":"Shao","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"2023111014150755300_B23","doi-asserted-by":"crossref","first-page":"603","DOI":"10.3390\/healthcare10040603","article-title":"Disease-specific health disparities: a targeted review focusing on race and ethnicity","volume":"10","author":"Cullen","year":"2022","journal-title":"Healthcare (Basel)"},{"key":"2023111014150755300_B24","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.3389\/fimmu.2018.02965","article-title":"Hidradenitis suppurativa: a systematic review integrating inflammatory pathways into a cohesive pathogenic model","volume":"9","author":"Vossen","year":"2018","journal-title":"Front Immunol"},{"issue":"6","key":"2023111014150755300_B25","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1016\/j.jaci.2020.12.651","article-title":"Epithelialized tunnels are a source of inflammation in hidradenitis suppurativa","volume":"147","author":"Navrazhina","year":"2021","journal-title":"J Allergy Clin Immunol"},{"issue":"9","key":"2023111014150755300_B26","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1001\/jamadermatol.2017.0904","article-title":"The follicular skin microbiome in patients with hidradenitis suppurativa and healthy controls","volume":"153","author":"Ring","year":"2017","journal-title":"JAMA Dermatol"},{"issue":"1","key":"2023111014150755300_B27","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41572-020-0149-1","article-title":"Hidradenitis suppurativa","volume":"6","author":"Sabat","year":"2020","journal-title":"Nat Rev Dis Primers"},{"issue":"12","key":"2023111014150755300_B28","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.3201\/eid2012.140064","article-title":"Bacterial pathogens associated with hidradenitis suppurativa, France","volume":"20","author":"Guet-Revillet","year":"2014","journal-title":"Emerg Infect Dis"},{"issue":"12","key":"2023111014150755300_B29","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1111\/exd.14214","article-title":"What causes hidradenitis suppurativa? -15 years after","volume":"29","author":"Zouboulis","year":"2020","journal-title":"Exp Dermatol"},{"issue":"1","key":"2023111014150755300_B30","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.det.2015.08.005","article-title":"Endocrinologic aspects of hidradenitis suppurativa","volume":"34","author":"Karagiannidis","year":"2016","journal-title":"Dermatol Clin"},{"issue":"6665","key":"2023111014150755300_B31","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1136\/bmj.298.6665.28","article-title":"Hidradenitis suppurativa associated with use of oral contraceptives","volume":"298","author":"Stellon","year":"1989","journal-title":"BMJ"},{"issue":"4","key":"2023111014150755300_B32","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/j.1365-2133.1993.tb03174.x","article-title":"Hidradenitis suppurativa as a presenting feature of premature adrenarche","volume":"129","author":"Lewis","year":"1993","journal-title":"Br J Dermatol"},{"key":"2023111014150755300_B33","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1016\/j.jaad.2015.07.051","article-title":"Hidradenitis suppurativa in the pediatric population","volume":"73","author":"Liy-Wong","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"2023111014150755300_B34","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jaad.2020.08.045","article-title":"Hidradenitis suppurativa in pediatric patients","volume":"86","author":"Choi","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"2023111014150755300_B35","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.jaad.2019.08.090","article-title":"Hidradenitis suppurativa: epidemiology, clinical presentation, and pathogenesis","volume":"82","author":"Goldburg","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"2023111014150755300_B36","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.det.2015.07.002","article-title":"The genetics of hidradenitis suppurativa","volume":"34","author":"Ingram","year":"2016","journal-title":"Dermatol Clin"},{"issue":"4","key":"2023111014150755300_B37","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1111\/bjd.18593","article-title":"No evidence that impaired Notch signaling differentiates hidradenitis suppurativa from other inflammatory skin diseases","volume":"182","author":"Frew","year":"2020","journal-title":"Br J Dermatol"},{"issue":"9","key":"2023111014150755300_B38","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1111\/jdv.16520","article-title":"Hidradenitis suppurativa in paediatric patients: a retrospective monocentric study in Germany and review of the literature","volume":"34","author":"Vaiopoulos","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"2023111014150755300_B39","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1080\/09546634.2021.1937484","article-title":"Pediatric hidradenitis suppurativa: epidemiology, disease presentation, and treatments","volume":"33","author":"Seivright","year":"2022","journal-title":"J Dermatolog Treat"},{"issue":"10","key":"2023111014150755300_B40","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s00403-020-02053-6","article-title":"Clinical characteristics of pediatric hidradenitis suppurativa: a cross-sectional multicenter study of 140 patients","volume":"312","author":"Riis","year":"2020","journal-title":"Arch Dermatol Res"},{"issue":"5","key":"2023111014150755300_B41","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/pde.15026","article-title":"A cross-sectional study of pediatric hidradenitis suppurativa and the value of the International Hidradenitis Suppurativa Severity Score System (IHS4) as a pediatric clinical trial inclusion criteria","volume":"39","author":"Bui","year":"2022","journal-title":"Pediatr Dermatol"},{"issue":"2","key":"2023111014150755300_B42","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1177\/12034754211039993","article-title":"Pediatric hidradenitis suppurativa: a cross-sectional study on clinical features and treatment approaches","volume":"26","author":"Garcovich","year":"2022","journal-title":"J Cutan Med Surg"},{"key":"2023111014150755300_B43","first-page":"623","article-title":"Axillary hyperhidrosis, apocrine bromhidrosis, hidradenitis suppurativa and familial benign pemphigus: surgical approach","volume-title":"Dermatologic Surgery: Principles and Practice","author":"Hurley","year":"1996","edition":"2nd ed."},{"issue":"5","key":"2023111014150755300_B44","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1111\/pde.14765","article-title":"Physical and psychosocial comorbidities of pediatric hidradenitis suppurativa: a retrospective analysis","volume":"38","author":"Seivright","year":"2021","journal-title":"Pediatr Dermatol"},{"issue":"3","key":"2023111014150755300_B45","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.jaad.2018.02.067","article-title":"Somatic and psychiatric comorbidities of hidradenitis suppurativa in children and adolescents","volume":"79","author":"Tiri","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"2023111014150755300_B46","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jdin.2021.11.007","article-title":"A visit guide for adolescent hidradenitis suppurativa: bridging the divide between pediatric and adult care","volume":"6","author":"Toledo","year":"2022","journal-title":"JAAD Int"},{"issue":"5","key":"2023111014150755300_B47","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.jaad.2021.01.059","article-title":"Comorbidity screening in hidradenitis suppurativa: evidence-based recommendations from the US and Canadian Hidradenitis Suppurativa Foundations","volume":"86","author":"Garg","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"2023111014150755300_B48","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.jaad.2019.08.034","article-title":"Association between obesity and hidradenitis suppurativa among children and adolescents: a population-based analysis in the United States","volume":"82","author":"Balgobind","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"2023111014150755300_B49","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1016\/j.jaad.2021.06.864","article-title":"A report of 1290 pediatric hidradenitis suppurativa hospitalizations: a nationwide analysis from the Kids\u2019 Inpatient Database","volume":"86","author":"Edigin","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"2023111014150755300_B50","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1159\/000481836","article-title":"Hidradenitis suppurativa: an Asian perspective from a Singaporean institute","volume":"4","author":"Choi","year":"2018","journal-title":"Skin Appendage Disord"},{"issue":"3","key":"2023111014150755300_B51","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1111\/pde.14131","article-title":"Weight counseling in pediatric hidradenitis suppurativa patients","volume":"37","author":"Reichert","year":"2020","journal-title":"Pediatr Dermatol"},{"issue":"2","key":"2023111014150755300_B52","doi-asserted-by":"crossref","first-page":"e20171603","DOI":"10.1542\/peds.2017-1603","article-title":"The metabolic syndrome in children and adolescents: shifting the focus to cardiometabolic risk factor clustering","volume":"140","author":"Magge","year":"2017","journal-title":"Pediatrics"},{"issue":"9","key":"2023111014150755300_B53","doi-asserted-by":"crossref","first-page":"e030579","DOI":"10.1136\/bmjopen-2019-030579","article-title":"Disease burden and cost of hidradenitis suppurativa: a retrospective examination of US administrative claims data","volume":"9","author":"Marvel","year":"2019","journal-title":"BMJ Open"},{"issue":"5","key":"2023111014150755300_B54","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1016\/j.jaad.2020.05.090","article-title":"New-onset depression among children, adolescents, and adults with hidradenitis suppurativa","volume":"83","author":"Wright","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"2023111014150755300_B55","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.jaad.2020.09.072","article-title":"Quality of life in hidradenitis suppurativa: a cross-sectional study of a pediatric population","volume":"84","author":"McAndrew","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"2023111014150755300_B56","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/bjd.17416","article-title":"Association between hidradenitis suppurativa and hospitalization for psychiatric disorders: a cross-sectional analysis of the National Inpatient Sample","volume":"181","author":"Patel","year":"2019","journal-title":"Br J Dermatol"},{"issue":"2","key":"2023111014150755300_B57","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/jdv.12567","article-title":"Psychiatric comorbidities in 3207 patients with hidradenitis suppurativa","volume":"29","author":"Shavit","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"2023111014150755300_B58","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/ijd.14639","article-title":"Hidradenitis suppurativa in a cohort of overweight and obese children and adolescents","volume":"59","author":"Linds\u00f8 Andersen","year":"2020","journal-title":"Int J Dermatol"},{"issue":"5","key":"2023111014150755300_B59","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1111\/bjd.13951","article-title":"Hidradenitis suppurativa-acne inversa: a relevant dermatosis in paediatric patients","volume":"173","author":"Bettoli","year":"2015","journal-title":"Br J Dermatol"},{"issue":"11","key":"2023111014150755300_B60","first-page":"1136","article-title":"Virilization caused by 21-hydroxylase deficiency and axillary sweat gland hyperplasia [in French]","volume":"115","author":"Jourdain","year":"1988","journal-title":"Ann Dermatol Venereol"},{"issue":"6","key":"2023111014150755300_B61","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1046\/j.1365-2230.2001.00876.x","article-title":"Early-onset hidradenitis suppurativa","volume":"26","author":"Palmer","year":"2001","journal-title":"Clin Exp Dermatol"},{"issue":"4","key":"2023111014150755300_B62","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1046\/j.1525-1470.1999.00077.x","article-title":"Prepubertal hidradenitis suppurativa: two case reports and review of the literature","volume":"16","author":"Mengesha","year":"1999","journal-title":"Pediatr Dermatol"},{"issue":"5","key":"2023111014150755300_B63","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.jpag.2021.02.002","article-title":"Care for adolescents with polycystic ovary syndrome: development and prescribing patterns of a multidisciplinary clinic","volume":"34","author":"Torres-Zegarra","year":"2021","journal-title":"J Pediatr Adolesc Gynecol"},{"issue":"4","key":"2023111014150755300_B64","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s13555-018-0264-z","article-title":"The comorbidity burden of hidradenitis suppurativa in the United States: a claims data analysis","volume":"8","author":"Kimball","year":"2018","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"1-2","key":"2023111014150755300_B65","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1159\/000487799","article-title":"Hidradenitis suppurativa associated with Down syndrome is characterized by early age at diagnosis","volume":"234","author":"Giovanardi","year":"2018","journal-title":"Dermatology"},{"issue":"3","key":"2023111014150755300_B66","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.jaad.2016.04.045","article-title":"Hidradenitis suppurativa (HS) and Down syndrome (DS): increased prevalence and a younger age of hidradenitis symptom onset","volume":"75","author":"Denny","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"2023111014150755300_B67","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/pde.14214","article-title":"Dermatologic conditions in Down syndrome: a single-center retrospective chart review","volume":"37","author":"Rork","year":"2020","journal-title":"Pediatr Dermatol"},{"issue":"1","key":"2023111014150755300_B68","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/pde.14012","article-title":"Follicular occlusion disorders in Down syndrome patients","volume":"37","author":"Firsowicz","year":"2020","journal-title":"Pediatr Dermatol"},{"issue":"3","key":"2023111014150755300_B69","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1111\/pde.14540","article-title":"The link between hidradenitis suppurativa and phylloid hypomelanosis in partial trisomy-13 mosaicism: new evidences and further genetic\/pathogenetic insights","volume":"38","author":"Forconi","year":"2021","journal-title":"Pediatr Dermatol"},{"issue":"5","key":"2023111014150755300_B70","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1001\/archdermatol.2009.37","article-title":"Phylloid hypomelanosis and mosaic partial trisomy 13: two cases that provide further evidence of a distinct clinicogenetic entity","volume":"145","author":"Gonz\u00e1lez-Ense\u00f1at","year":"2009","journal-title":"Arch Dermatol"},{"issue":"4","key":"2023111014150755300_B71","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1159\/000342884","article-title":"Phylloid pattern of hypomelanosis closely related to chromosomal abnormalities in the 13q detected by SNP array analysis","volume":"225","author":"Faletra","year":"2012","journal-title":"Dermatology"},{"issue":"3","key":"2023111014150755300_B72","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/pde.14949","article-title":"Severe recalcitrant hidradenitis suppurativa in a 2-year-old boy with partial trisomy 13","volume":"39","author":"Keyes","year":"2022","journal-title":"Pediatr Dermatol"},{"issue":"6","key":"2023111014150755300_B73","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.jdcr.2020.04.002","article-title":"Hidradenitis suppurativa in a long-lived patient with trisomy 13","volume":"6","author":"Tabata","year":"2020","journal-title":"JAAD Case Rep"},{"issue":"2","key":"2023111014150755300_B74","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1525-1470.2010.01098.x","article-title":"Extensive comedonal and cystic acne in Patau syndrome","volume":"27","author":"Torrelo","year":"2010","journal-title":"Pediatr Dermatol"},{"issue":"7","key":"2023111014150755300_B75","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1002\/ajmg.a.38251","article-title":"Acne conglobata in a long-term survivor with trisomy 13, accompanied by selective IgM deficiency","volume":"173","author":"Inoue","year":"2017","journal-title":"Am J Med Genet A"},{"issue":"3","key":"2023111014150755300_B76","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jaad.2003.12.042","article-title":"A novel connexin 26 gene mutation associated with features of the keratitis-ichthyosis-deafness syndrome and the follicular occlusion triad","volume":"51","author":"Montgomery","year":"2004","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"2023111014150755300_B77","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1159\/000509042","article-title":"KID Syndrome and hidradenitis suppurativa: a rare association responding to surgical treatment","volume":"7","author":"Bettoli","year":"2021","journal-title":"Skin Appendage Disord"},{"issue":"1","key":"2023111014150755300_B78","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/pde.14417","article-title":"Prevalence of inflammatory bowel disease among pediatric patients with hidradenitis suppurativa and the potential role of screening with fecal calprotectin","volume":"38","author":"Lloyd-McLennan","year":"2021","journal-title":"Pediatr Dermatol"},{"issue":"4","key":"2023111014150755300_B79","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1097\/MPG.0000000000000185","article-title":"Hidradenitis suppurativa and pediatric Crohn disease","volume":"60","author":"Natarajan","year":"2015","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"2","key":"2023111014150755300_B80","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.clindermatol.2020.10.016","article-title":"PASH, PAPASH, PsAPASH, and PASS: the autoinflammatory syndromes of hidradenitis suppurativa","volume":"39","author":"Garcovich","year":"2021","journal-title":"Clin Dermatol"},{"issue":"11","key":"2023111014150755300_B81","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1111\/jdv.14464","article-title":"Recognizing syndromic hidradenitis suppurativa: a review of the literature","volume":"31","author":"Gasparic","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"8","key":"2023111014150755300_B82","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1001\/archdermatol.2010.161","article-title":"Development and validation of Skindex-Teen, a quality-of-life instrument for adolescents with skin disease","volume":"146","author":"Smidt","year":"2010","journal-title":"Arch Dermatol"},{"issue":"1","key":"2023111014150755300_B83","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jaad.2019.02.068","article-title":"North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian Hidradenitis Suppurativa Foundations: part II: topical, intralesional, and systemic medical management","volume":"81","author":"Alikhan","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"2023111014150755300_B84","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.jaad.2021.09.058","article-title":"Wound dressings improve quality of life for hidradenitis suppurativa patients","volume":"86","author":"Schneider","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"2023111014150755300_B85","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/j.1365-4362.1983.tb02150.x","article-title":"Topical treatment of hidradenitis suppurativa with clindamycin","volume":"22","author":"Clemmensen","year":"1983","journal-title":"Int J Dermatol"},{"issue":"6","key":"2023111014150755300_B86","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1111\/bjd.19337","article-title":"Efficacy and safety of topical resorcinol 15% as long-term treatment of mild-to-moderate hidradenitis suppurativa: a valid alternative to clindamycin in the panorama of antibiotic resistance","volume":"183","author":"Molinelli","year":"2020","journal-title":"Br J Dermatol"},{"issue":"4","key":"2023111014150755300_B87","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1111\/bjd.19136","article-title":"Dapsone therapy for hidradenitis suppurativa","volume":"183","author":"Murray","year":"2020","journal-title":"Br J Dermatol"},{"issue":"6","key":"2023111014150755300_B88","doi-asserted-by":"crossref","first-page":"e15161","DOI":"10.1111\/dth.15161","article-title":"Dapsone in hidradenitis suppurativa: a case series of 56 patients","volume":"34","author":"L\u00f3pez-Llunell","year":"2021","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"9","key":"2023111014150755300_B89","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1111\/ijd.14036","article-title":"Ertapenem - a potent treatment for clinical and quality of life improvement in patients with hidradenitis suppurativa","volume":"57","author":"Braunberger","year":"2018","journal-title":"Int J Dermatol"},{"issue":"6","key":"2023111014150755300_B90","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1159\/000524121","article-title":"Intralesional treatments in hidradenitis suppurativa: a systematic review","volume":"238","author":"Cuenca-Barrales","year":"2022","journal-title":"Dermatology"},{"issue":"2","key":"2023111014150755300_B91","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1177\/12034754211049711","article-title":"Biologic use in pediatric patients with hidradenitis suppurativa: a systematic review","volume":"26","author":"Sachdeva","year":"2021","journal-title":"J Cutan Med Surg"},{"issue":"5","key":"2023111014150755300_B92","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1208\/s12248-019-0363-5","article-title":"Model-informed drug development approach supporting approval of adalimumab (HUMIRA) in adolescent patients with hidradenitis suppurativa: a regulatory perspective","volume":"21","author":"Bi","year":"2019","journal-title":"AAPS J"},{"issue":"4","key":"2023111014150755300_B93","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jaad.2008.11.898","article-title":"A prospective clinical trial of open-label etanercept for the treatment of hidradenitis suppurativa","volume":"60","author":"Lee","year":"2009","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"2023111014150755300_B94","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1001\/jamadermatol.2021.4805","article-title":"Drug survival of biologics in patients with hidradenitis suppurativa","volume":"158","author":"Ring","year":"2022","journal-title":"JAMA Dermatol"},{"issue":"5","key":"2023111014150755300_B95","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1001\/archdermatol.2010.72","article-title":"Treatment of hidradenitis suppurativa with etanercept injection","volume":"146","author":"Adams","year":"2010","journal-title":"Arch Dermatol"},{"key":"2023111014150755300_B96","unstructured":"US Food and Drug Administration . Humira (adalimumab) [package insert]. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/125057s394lbl.pdf. Accessed June 19, 2022"},{"issue":"2","key":"2023111014150755300_B97","doi-asserted-by":"crossref","first-page":"455","DOI":"10.3390\/biomedicines10020455","article-title":"Paradoxical hidradenitis suppurativa during biologic therapy, an emerging challenge: a systematic review","volume":"10","author":"Ruggiero","year":"2022","journal-title":"Biomedicines"},{"issue":"6","key":"2023111014150755300_B98","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1016\/j.jaad.2020.02.005","article-title":"Secukinumab in the treatment of moderate to severe hidradenitis suppurativa: results of an open-label trial","volume":"82","author":"Casseres","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"2023111014150755300_B99","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/bjd.17822","article-title":"Open-label, investigator-initiated, single-site exploratory trial evaluating secukinumab, an anti-interleukin-17A monoclonal antibody, for patients with moderate-to-severe hidradenitis suppurativa","volume":"181","author":"Prussick","year":"2019","journal-title":"Br J Dermatol"},{"issue":"5","key":"2023111014150755300_B100","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1111\/pde.14631","article-title":"Vaccines: considerations for pediatric dermatology patients on immunosuppressive agents","volume":"38","author":"Munshi","year":"2021","journal-title":"Pediatr Dermatol"},{"issue":"3","key":"2023111014150755300_B101","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.jaad.2021.12.005","article-title":"Trends in the prescribing pattern of spironolactone for acne and hidradenitis suppurativa in adolescents","volume":"87","author":"Horissian","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"2023111014150755300_B102","first-page":"697","article-title":"The role of oral contraceptive pills in hidradenitis suppurativa: a cohort study","volume":"11","author":"Montero-Vilchez","year":"2021","journal-title":"Life (Basel)"},{"issue":"1","key":"2023111014150755300_B103","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/bjd.17900","article-title":"KITTEN following CAT on the long-term use of rifampicin in hidradenitis suppurativa and effectiveness of oral contraceptives","volume":"181","author":"Yazdanyar","year":"2019","journal-title":"Br J Dermatol"},{"issue":"9","key":"2023111014150755300_B104","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1001\/jamadermatol.2015.34","article-title":"Low usefulness of potassium monitoring among healthy young women taking spironolactone for acne","volume":"151","author":"Plovanich","year":"2015","journal-title":"JAMA Dermatol"},{"issue":"1","key":"2023111014150755300_B105","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/ced.14847","article-title":"Antiandrogen therapy in hidradenitis suppurativa: finasteride for females","volume":"47","author":"Babbush","year":"2022","journal-title":"Clin Exp Dermatol"},{"issue":"12","key":"2023111014150755300_B106","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.36849\/JDD.2020.5447","article-title":"Metformin as adjunctive therapy for pediatric patients with hidradenitis suppurativa","volume":"19","author":"Moussa","year":"2020","journal-title":"J Drugs Dermatol"},{"issue":"1","key":"2023111014150755300_B107","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0190-9622(99)70530-X","article-title":"Long-term results of isotretinoin in the treatment of 68 patients with hidradenitis suppurativa","volume":"40","author":"Boer","year":"1999","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"2023111014150755300_B108","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/S0190-9622(84)70199-X","article-title":"Evaluation of isotretinoin treatment of hidradenitis suppurativa","volume":"11","author":"Dicken","year":"1984","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"2023111014150755300_B109","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1080\/09546634.2019.1670779","article-title":"Isotretinoin in the treatment of hidradenitis suppurativa: a retrospective study","volume":"32","author":"Patel","year":"2021","journal-title":"J Dermatolog Treat"},{"issue":"3","key":"2023111014150755300_B110","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1177\/1203475418823529","article-title":"Combination therapies for hidradenitis suppurativa: a retrospective chart review of 31 patients","volume":"23","author":"McPhie","year":"2019","journal-title":"J Cutan Med Surg"},{"issue":"3","key":"2023111014150755300_B111","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/ijd.13428","article-title":"Hidradenitis suppurativa treated with tetracycline in combination with colchicine: a prospective series of 20 patients","volume":"56","author":"Armyra","year":"2017","journal-title":"Int J Dermatol"},{"issue":"3","key":"2023111014150755300_B112","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1111\/pde.14955","article-title":"Surgical deroofing in pediatric patients with hidradenitis suppurativa","volume":"39","author":"Leszczynska","year":"2022","journal-title":"Pediatr Dermatol"},{"issue":"3","key":"2023111014150755300_B113","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.jaad.2021.10.060","article-title":"Alexandrite laser as an adjuvant therapy in the management of mild to moderate hidradenitis suppurativa: a controlled prospective clinical study","volume":"87","author":"Molinelli","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"2023111014150755300_B114","first-page":"e15210","article-title":"Hyperhidrosis treatments in hidradenitis suppurativa: a systematic review","volume":"35","author":"Shih","year":"2022","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"7","key":"2023111014150755300_B115","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1111\/ijd.15459","article-title":"Treatment of hidradenitis suppurativa with tetracycline, doxycycline, or lymecycline: a prospective study","volume":"60","author":"J\u00f8rgensen","year":"2021","journal-title":"Int J Dermatol"},{"issue":"1","key":"2023111014150755300_B116","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/bjd.19867","article-title":"Oral clindamycin and rifampicin in the treatment of hidradenitis suppurativa-acne inversa in patients of paediatric age: a pilot prospective study","volume":"185","author":"Bettoli","year":"2021","journal-title":"Br J Dermatol"},{"key":"2023111014150755300_B117","unstructured":"US Food and Drug Administration . Invanz (ertapenem) [package insert]. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/021337s038lbl.pdf. Accessed July 4, 2022"},{"issue":"5","key":"2023111014150755300_B118","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa1504370","article-title":"Two phase 3 trials of adalimumab for hidradenitis suppurativa","volume":"375","author":"Kimball","year":"2016","journal-title":"N Engl J Med"},{"issue":"9","key":"2023111014150755300_B119","first-page":"e15691","article-title":"Infliximab in hidradenitis suppurativa: a systematic review and meta-analysis","volume":"35","author":"Shih","year":"2022","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"4","key":"2023111014150755300_B120","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1159\/000521860","article-title":"An anti-interleukin-17A monoclonal antibody, ixekizumab, in the treatment of resistant hidradenitis suppurativa: a case series","volume":"8","author":"Esme","year":"2022","journal-title":"Skin Appendage Disord"},{"issue":"3","key":"2023111014150755300_B121","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/ajd.12362","article-title":"A case series of 20 women with hidradenitis suppurativa treated with spironolactone","volume":"56","author":"Lee","year":"2015","journal-title":"Australas J Dermatol"},{"issue":"5","key":"2023111014150755300_B122","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/pde.13216","article-title":"Hidradenitis suppurativa in children treated with finasteride-a case series","volume":"34","author":"Mota","year":"2017","journal-title":"Pediatr Dermatol"},{"issue":"10","key":"2023111014150755300_B123","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.ad.2019.01.030","article-title":"Systemic steroids in the management of moderate-to-severe hidradenitis suppurativa","volume":"111","author":"Duarte","year":"2020","journal-title":"Actas Dermosifiliogr (Engl Ed)"},{"issue":"6","key":"2023111014150755300_B124","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.jaad.2016.06.049","article-title":"Intralesional triamcinolone for flares of hidradenitis suppurativa (HS): a case series","volume":"75","author":"Riis","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"2023111014150755300_B125","doi-asserted-by":"crossref","first-page":"247","DOI":"10.3109\/09546634.2015.1088128","article-title":"Cyclosporine treatment of severe hidradenitis suppurativa--a case series","volume":"27","author":"Anderson","year":"2016","journal-title":"J Dermatolog Treat"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2022-061049\/1565617\/peds_2022061049.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2022-061049\/1565617\/peds_2022061049.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,19]],"date-time":"2024-10-19T04:41:35Z","timestamp":1729312895000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/151\/5\/e2022061049\/191145\/Hidradenitis-Suppurativa-in-Pediatric-Patients"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,27]]},"references-count":125,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,4,27]]},"published-print":{"date-parts":[[2023,5,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2022-061049","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,27]]},"article-number":"e2022061049"}}